A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 27 May 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Copanlisib (Primary)
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms CHRONOS-2
Sponsors Bayer; Bayer HealthCare

29 Dec 2022 Status changed from active, no longer recruiting to completed.
06 Dec 2021 Planned End Date changed from 30 Nov 2021 to 30 Nov 2022.
06 Dec 2021 Planned primary completion date changed from 30 Nov 2021 to 23 Nov 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com